Altered Gut Microbiome in Parkinson’s Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model

Anastazja M. Gorecki1,2, Leah Preskey3,4, Megan C. Bakeberg1,2, Jade E. Kenna1,2, Christi Gildenhuys1,5, Gabriella MacDougall1,5, Sarah A. Dunlop1,6, Frank L. Mastaglia1,2, P. Anthony Akkari1,2,7, Frank Koengten3,4 and Ryan S. Anderton1,2,5*

1 Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia, 2 Centre for Neuromuscular & Neurological Disorders, The University of Western Australia, Crawley, WA, Australia, 3 Ozone Pty Ltd., Bentley, WA, Australia, 4 School of Medicine, The University of Notre Dame Australia, Fremantle, WA, Australia, 5 Institute for Health Research and School of Health Sciences, The University of Notre Dame Australia, Fremantle, WA, Australia, 6 School of Biological Sciences, The University of Western Australia, Nedlands, WA, Australia, 7 The Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA, Australia

The interaction between the gut microbiota and alpha-synuclein (αSyn) aggregation in Parkinson’s disease (PD) is receiving increasing attention. The objective of this study was to investigate gut microbiota, and effects of an inflammatory lipopolysaccharide (LPS) trigger in a human αSyn over-expressing mouse model of PD (Thy1-αSyn). Stool samples from patients with confirmed PD and Thy1-αSyn mice were analyzed using 16S ribosomal RNA sequencing. Compared to healthy controls, the relative abundance of mucin-degrading Verrucomicrobiae and LPS-producing Gammaproteobacteria were greater in PD patients. In mice, the abundance of Gammaproteobacteria was negligible in both Thy1-αSyn and wild-type (WT) animals, while Verrucomicrobiae were reduced in Thy1-αSyn mice. The effect of LPS on intestinal barrier function was investigated in vitro using intestinal epithelial (IEC-6) cells, and in vivo via administration of LPS in drinking water to Thy1-αSyn mice. Acute exposure to LPS in vitro resulted in a reduction and altered distribution of the tight junction markers ZO-1 and e-Cadherin around the cell membrane in IEC-6 cells, and in vivo via administration of LPS in drinking water to Thy1-αSyn mice. Acute exposure to LPS in vitro resulted in a reduction and altered distribution of the tight junction markers ZO-1 and e-Cadherin around the cell membrane in IEC-6 cells, as shown by immunohistochemistry. LPS administration in Thy1-αSyn mice resulted in the emergence of early motor manifestations at 10 weeks, compared to untreated mice who were still asymptomatic at this age. This study reaffirms that an altered microbiome exists in patients with PD, and supports the notion of a proinflammatory gut microbiome environment as a trigger for PD pathogenesis.

Keywords: Parkinson’s disease, microbiome, lipopolysaccharide, Gammaproteobacteria, Thy1-αSyn, gastrointestinal
INTRODUCTION

Parkinson’s disease (PD) has traditionally been characterized by motor impairment but is now considered a multisystemic disorder displaying a plethora of non-motor symptoms (Chaudhuri et al., 2006; Emamzadeh and Surguchov, 2018; Greenland et al., 2019). For example, people with PD frequently report various gastrointestinal complaints including constipation and nausea, and have prolonged intestinal transit time, often years prior to their PD diagnosis (Martinez-Martin et al., 2011; Lin et al., 2014; Fasano et al., 2015; Adams-Carr et al., 2016). A key feature of the disease is the formation of insoluble alpha-synuclein (αSyn) aggregates within neurons (Goedert et al., 2013), contributing to the loss of dopaminergic neurons in the basal ganglia. This Lewy body pathology also occurs more widely throughout the central and peripheral nervous systems, including the enteric nervous system (Beach et al., 2010).

The concept that PD is initiated following continuous gut aggravation has gathered significant momentum in recent years. Enteric αSyn is associated with greater intestinal permeability (Forsyth et al., 2011), and a positive relationship between inflammatory bowel diseases and future PD risk is evident in various populations (Lin et al., 2016; Peter et al., 2018; Weimers et al., 2018). Individuals with PD also exhibit an imbalanced gut microbiome (dysbiosis) and gastrointestinal inflammation (Keshavarzian et al., 2015; Hill-Burns et al., 2017; Heintz-Buschart et al., 2018). Various studies report similar trends in the microbial composition of people with PD, where commensal bacteria (e.g., phylum Firmicutes) are reduced, while pathogenic gram-negative bacteria (Proteobacteria, Enterobacteriaceae, Escherichia sp.) and mucin-degrading Verrucomicrobiaceae are increased (Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016; Hill-Burns et al., 2017; Li et al., 2017). Moreover, bacterial treatments in vitro and fecal microbial transplants in vivo also support the role of the gut microbiome in αSyn aggregation, gastrointestinal inflammation and motor symptom development (Sampson et al., 2016; Choi et al., 2018; Sun et al., 2018).

Gram-negative bacteria, elevated in people with PD, produce lipopolysaccharide (LPS), an endotoxin associated with intestinal inflammation (Guo et al., 2015; Nighot et al., 2017). Interestingly, the abundance of gram-negative Enterobacteriaceae is positively correlated with the degree of postural instability and gait difficulty in individuals with PD (Scheperjans et al., 2015). In rodent models, LPS administration mirrors PD pathology. Direct stereotaxic injection of LPS into the substantia nigra causes microglial inflammation, oxidative stress, cellular apoptosis, reduced dopamine production and motor impairments (Sharma and Nehru, 2015). In the periphery, an intraperitoneal dose of LPS increased αSyn expression and intestinal permeability in the large intestine (Kelly et al., 2014), while chronic intranasal instillation resulted in progressive hypokinesia, selective dopaminergic neuronal loss and nigrostriatal αSyn aggregation (He et al., 2013). Recently, intrarectal administration of Proteus mirabilis-derived LPS to mice was shown to reduce the tight junction cell marker occludin but increased tumor necrosis factor alpha levels, and caused toll-like receptor 4 overexpression in the colon 16 days after treatment (Choi et al., 2018). These effects extended to the brain, with microglial activation throughout nigrostriatal regions and αSyn aggregation throughout central and enteric neurons, supporting evidence for environmentally-triggered gut-brain pathology in the context of PD (Choi et al., 2018). With enteric levels of αSyn being associated with greater intestinal permeability and LPS translocation across the intestinal barrier in people with PD (Forsyth et al., 2011), there is the potential for gut microbiota to induce αSyn propagation along peripheral nerves toward the brainstem, and brain more widely.

As such, early gastrointestinal dysfunction in people with PD may be more than a prodromal symptom, but rather an early contributing factor for αSyn pathology in susceptible individuals. Therefore, the objective of this study was to investigate the gut microbiota in PD patients and αSyn over-expressing mice. Mice over-expressing human αSyn (C57BL-6N-Tg (Thy1-SNCA) 61Mjff/J) exhibit nigrostriatal pathology and dopamine depletion (Chesselet et al., 2012), and were chosen for this study as a progressive model of PD which allows for a clinically relevant exploration of the gut microbiome prior to the onset of motor impairments. The identification of pro-inflammatory Gammaproteobacteria in PD patients but not the genetic rodent model led to the exploration of LPS as an environmental inflammatory trigger for PD in intestinal epithelial cells and αSyn over-expressing mice.

MATERIALS AND METHODS

Human Participants

Participants were recruited from The Movement Disorders Clinics at the Perron Institute for Neurological and Translational Science. Patients (n = 14) and healthy controls (n = 7) with no history of antibiotic or non-steroidal anti-inflammatory drug use in the previous 3 months were included in this study. All patients were confirmed to have idiopathic Parkinson’s disease by a movement disorders neurologist, in accordance with the United Kingdom Brain Bank criteria. Human Research and Ethics approval was granted from The University of Western Australia (Approval number RA/4/20/4470). All participants gave written informed consent in accordance with the Declaration of Helsinki. Clinical and demographic characteristics of the participants recruited are presented in Supplementary Table S1.

Participant Clinical Information and Fecal Sample Collection

Relevant participant demographic and clinical information was obtained from healthy controls and patients. At the time of all assessments, patient response to their dopaminergic medications was at optimum levels (“ON” period), and motor symptoms were evaluated using the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III and Hoehn and Yahr Scale, as previously described (Evans et al., 2017). For subsequent analyses the patients were divided into mild (n = 7) and severe (n = 7) groups based on MDS-UPDRS III and Hoehn and Yahr scores.
Rectal swab samples were used to collect stool samples for DNA extraction and 16S rRNA sequencing. Samples were obtained by inserting a dual Dacron swab moistened with sterile liquid Stuart medium (Becton Dickenson, Sparks, MD) 1–2 cm past the anal verge and rotating the swab gently through 360°. Collected swabs were stored in liquid Stuart medium at −20°C prior to DNA extraction.

**Wild-Type and Thy1-SNCA Mice**

Mice overexpressing wild-type human αSyn (Thy1-SNCA) throughout the central and enteric nervous systems exhibit progressive αSyn pathology, nigrostriatal dopamine depletion and inflammation coupled with motor and non-motor symptoms, including slowed colonic transit time and constipation (Chesselet et al., 2012; Hallett et al., 2012). Four male hemizygous mice overexpressing wild type human α-Synuclein (C57BL-6N-Tg (Thy1-SNCA)15Mjff/J) (αSyn) were acquired from Jackson Laboratories (Jax Stock #017682) (Ouyang, 2012) and bred to female C57BL/6N mice to generate the male and female heterozygous offspring used in this study. Wild-type (WT) controls and αSyn littermates were housed together and received food and water ad libitum. All animals were maintained on a 12-hour light-dark cycle with constant temperature and humidity at the same facility. For animal studies, fecal pellets were collected from individual WT controls and αSyn mice at 8 weeks of age. All animal husbandry and experiments were approved by the Ozgene Animal Ethics Committee.

**Functional Assessments**

**Adhesive Removal**

Small adhesive stickers (30 mm × 40 mm) were placed on the nasal bridge. Timing began once the mouse was released into the home cage. Time between first paw contact with the sticker and removal of the sticker was measured. The mean of all three replicates per day was used for further analysis (Guyenet et al., 2010).

**Hind Limb Clasping Reflex**

The mouse was suspended in the air by its tail, and the distance of the hind limbs to the abdomen for the majority of 10 s was scored on a 4-point scale, as previously reported (Sampson et al., 2016). A score of 0 was given if hind limbs were constantly splayed outward from the abdomen, a score of 1 if one hind limb was retracted toward abdomen for more than 50% of the time sustained, and two if both limbs are retracted. A maximum score of three indicates both hind limbs are entirely retracted and touching the abdomen for more than 50% of the suspended time (Guyenet et al., 2010). Retraction of the hind limbs during the tail suspension test is considered to be a dystonic type of reaction indicative of striatal dysfunction (Zhang et al., 2014; Sampson et al., 2016).

**DNA Extraction and 16S rRNA Sequencing**

Human stool swabs and mouse fecal pellets were sent to the Australian Genome Research Facility (AGRF, Australia) for total nucleic acid extraction, 16S rRNA sequencing and microbial diversity mapping of the V3-V4 region, as previously described (Reyes et al., 2010). For this study, relative abundance and number of different Operational Taxonomic Units (OTU, diversity) were provided from the data sequencing.

**Small Intestinal Epithelial Cell Culture**

Rat small intestinal epithelial cells (IEC-6; ECACC 88071401), a model for the crypt region which regulates intestinal permeability (Kimura et al., 1997) were supplied by CellBank Australia (WestMead, NSW, Australia). IEC-6 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/5% fetal calf serum (FCS; Thermo Fisher, Melbourne, Australia) containing penicillin (20 U/ml) and streptomycin (20 mg/ml) at 37°C in a CO2 incubator (5% CO2, 95% air balance, 97% humidity). For experimentation, IEC-6 cells were seeded in 24-well plates at approximately 5 × 104 cells/well in 500 µl DMEM/5% FCS and used for studies 1–3 days after plating.

**Lipopolysaccharide Treatment**

Both IEC-6 cells and mice were treated with LPS (E. coli 055: B5, Sigma, Australia). For *in vitro* studies, culture media was aspirated from each well and replaced with DMEM/5% FCS containing LPS (10 µg/ml final concentration) and maintained at 37°C in a CO2 incubator (5% CO2, 95% air balance, 97% humidity) for 4 h. For animal studies, animals were provided with drinking water containing LPS (5 µg/ml) diluted in 0.075 M sucrose. LPS was provided for 15 h starting at lights out (6:00 pm) for 10 consecutive days starting at 8 weeks of age. A low dose of oral LPS for 10 days was chosen to mimic clinically relevant chronic exposure to luminal LPS produced by gut microbes. Unlike systemic LPS administration, oral LPS does not cause severe neurological deficits (Suffredini et al., 1999; Inagawa et al., 2011).

**Tissue Preparation**

Cervical dislocation and tissue harvesting were performed at various timepoints following behavioral assessments. Small and large intestines were flushed with PBS and optimal cutting temperature (OCT) compound (Tissue-Tek), and fresh-frozen in liquid nitrogen. Tissue was thawed to −20°C and subsequently sectioned onto glass slides using a cryostat microtome (CM1510, Leica, Germany) for immunofluorescence analysis.

**Protein Extraction and Western Blots Analysis**

Western blot analysis was completed as previously described (MacDougall et al., 2017). Briefly, 15 mg of tissue homogenate from each sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using pre-cast Bis-Tris gels (10%; Bio-Rad). Membranes were blocked in PBS-Tween 20 (0.1%) with ovalbumin (1 mg/ml) for 1 h, followed by overnight incubation (4°C) with alpha-synuclein (1:1000; Abcam, 212184), human alpha-synuclein (1:1000; Invitrogen 701085), or β-tubulin (1:3000; Invitrogen MA1-118) diluted in 1% PBS-T, and 1-hour incubation at room temperature with goat anti-rabbit IgG (1:10000; Abcam, 212184) secondary antibody. Membranes were washed and incubated with horseradish peroxidase-conjugated anti-goat IgG (1:10000; Abcam, 212184) secondary antibody for 1 hour, followed by washing and detection using an enhanced chemiluminescence kit (ECL, Amersham, Australia).
anti-rabbit Star bright blue 700 (1:5000; Bio-Rad 12004162) or goat anti-mouse IgG HRP (1:20000; Bio-Rad 1705047) secondary antibodies. All membranes were visualized using ChemiDoc Imaging System (Bio-Rad). Quantification and densitometry were performed using ImageJ software (National Institutes of Health, United States).

Immunocytochemistry and Immunofluorescence
Mounted tissue sections or IEC-6 cells were fixed in a 1:1 solution of methanol/acetate and incubated at −20°C for 15 min. After aspiration of the fixative, IEC-6 cells and mounted tissue sections were air-dried for 30 min at room temperature. IEC-6 cells were then washed in PBS + 0.2% Tween, and then blocked in 10% bovine serum albumin (BSA) for 15 min. Tissue sections were gently rinsed with PBS and blocked in 10% goat serum/1% BSA in 0.05% Triton X-100 PBS for 2 h. IEC-6 cells and tissue sections were incubated with TLR4 (1:200; Thermo Fisher), ZO-1 (1:400; Thermo Fisher), e-Cadherin (1:400; Thermo Fisher), ZO-1 and e-Cadherin in IEC-6 Cells

Immunofluorescence
Whole brain homogenates and sections from Thy1-αSyn-overexpressing (Thy1-αSyn) mice and wild-type littermates (WT) were analyzed for levels of αSyn at multiple time points. At 4, 8, and 12 weeks of age, human αSyn was detected in Thy1-αSyn mice but not the WT controls (Figure 2A). Interestingly, total αSyn protein progressively increased between time points, with a ~1.5-fold increase in 4-week old, and ~3 fold in 8 and 12-week old Thy1-αSyn brain tissue, when compared to WT controls. No significant differences in hindlimb clasp reflex (striatal dysfunction, Figure 2B) or nasal adhesive removal (fine motor control, Figure 2C) were observed from weeks 4–12 between Thy1-αSyn and WT mice. No differences in general locomotion or behavior were observed between the Thy1-αSyn and WT mice. The mean weight of Thy1-αSyn mice was lower than their WT littermates, with a mean weight 16% lower than WT controls at 12 weeks of age (Figure 2D and Supplementary Table S2).

Bacterial Diversity and Abundance Are Altered in Thy1-αSyn Mice
Thy1-αSyn and WT mice groups both showed a high mean microbial diversity, and Thy1-αSyn (347.6 ± 22.81) mice had a significantly greater diversity than WT controls (306.3 ± 21.55, p < 0.05). Overall classes Bacteroidia, Clostridia and Bacilli comprised the majority of the microbiome in both WT and Thy1-αSyn mice (Figure 3A). The six most abundant bacterial classes were compared between animal groups (Figure 3B). Verrucomicrobiae was significantly lower in Thy1-αSyn mice (mean relative abundance ± SD = 0.0007 ± 0.0009) than WT controls (0.0059 ± 0.0038, p < 0.05). However, the mean relative abundance of classes Bacteroidia, Clostridia, Bacilli, Coriobacteria and Betaproteobacteria were not significantly altered between Thy1-αSyn and WT mice.

LPS Alters Quantity and Distribution of ZO-1 and e-Cadherin in IEC-6 Cells in vitro
As previously mentioned, gram-negative Gammaproteobacteria produce LPS, an inflammatory endotoxin. Given the increased abundance of Gammaproteobacteria in the pilot clinical cohort and the inferred increase in intestinal LPS, we next explored
FIGURE 1 | Mean class abundance in people with Parkinson's disease and healthy controls. Individuals with Parkinson's disease (PD) were grouped by a clinician. Pie charts illustrate the mean relative abundance of bacterial classes in healthy controls and individuals with mild or severe PD (A). Comparison of the six most abundant classes demonstrates a significant increase in Gammaproteobacteria in mild PD compared to controls (621.22× fold, \( p < 0.05 \)), and significantly elevated levels of Verrucomicrobiae in severe PD patients, when compared to mild PD patients (4.35× fold, \( p < 0.05 \)) (B).

the effects of LPS on IEC-6 intestinal epithelial cells in vitro. The expression of the known LPS receptor, TLR4, was confirmed in IEC-6 cells (Figure 4A). Acute exposure of IEC-6 cells to LPS (10 µg/ml) did not affect cell viability or expression of TNF-α when compared to untreated cultures (Supplementary Figure S1). However, LPS treatment resulted in a noticeable reduction and altered distribution of the tight junction proteins ZO-1 (Figure 4B) and e-Cadherin in cells (Figure 4C) when compared to untreated IEC-6 cells.

LPS Administration Leads to the Emergence of Motor Symptoms in Thy1-αSyn Mice

After LPS consumption (10 µg/ml) in drinking water for 12 nights, treated Thy1-αSyn mice had a significantly increased mean hindlimb clasp reflex (HC) score during the tail suspension test compared to baseline (Figure 5A) and untreated 10-week old Thy1-αSyn (Figure 5E), whose score remained normal (\( p < 0.05 \)). WT groups maintained a normal HC score at all time points (Figures 5B,F). A non-significant trend for slower adhesive removal was evident when comparing LPS Thy1-αSyn mice (1.37s ± 1.09) to baseline (0.83s ± 0.95) (Figure 5C) and untreated 10-week old Thy1-αSyn mice (0.7s ± 0.81) (Figure 5G). LPS WT mice showed a non-significant trend for faster removal (1.82s ± 1.14) than baseline (3.29s ± 5.57) (Figure 5D) with no difference compared to untreated 10-week old WT (3.04s ± 2.69) (Figure 5H). After LPS consumption, Thy1-αSyn mice also displayed slower locomotion and altered behavior compared to baseline and WT animals.
FIGURE 2 | Progressively increasing brain αSyn levels are not associated with notable motor impairments in 12-week old mice. Compared to WT mice, the Thy1-αSyn mice exhibit progressively increasing human and total αSyn in whole brain lysates compared to WT mice at 4, 8 and 12 weeks of age (A). There were no significant differences in hind-limb clasp scores (B) or nasal adhesive removal (C) between animal groups. The weight of both groups increased with age, where the Thy1-αSyn mice consistently weighed less (D).

Although it is unlikely to have impacted the observed motor impairments, both Thy1-αSyn and WT LPS-treated mice were significantly heavier than baseline. Treated Thy1-αSyn mice were also significantly heavier than untreated mice at 10-week old (Supplementary Figure S2). The observed weight gain is a possible consequence of the sucrose in the LPS mixture.

DISCUSSION

Previous studies have reported an altered gut microbiome and gastrointestinal inflammation in individuals with PD (Forsyth et al., 2011; Keshavarzian et al., 2015; Hill-Burns et al., 2017; Heintz-Buschart et al., 2018), however, it remains to be seen whether such changes are causative or symptomatic of the disease. Despite a small sample size, our data demonstrated a significant shift toward a dysbiotic gut microbiome in Australian people with PD, due to reduced diversity and altered relative class abundance. Subsequently, this study investigated the relationship between αSyn, motor impairments and microbial-derived LPS in an αSyn-overexpressing animal model of PD.

In contrast to patients with mild PD, those with more advanced disease were found to have significantly reduced bacterial diversity compared to healthy controls, in keeping with
The findings of previous studies (Keshavarzian et al., 2015; Unger et al., 2016; Hill-Burns et al., 2017; Li et al., 2017). Lower bacterial diversity has been linked to intestinal inflammation and immune activation, and has also been reported in inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, as well as obesity (Ott et al., 2004; Eckburg et al., 2005; Ley et al., 2006; Manichanh et al., 2006; Frank et al., 2007; Dicksved et al., 2008; Carroll et al., 2011).

Our data demonstrated a significant increase in Gammaproteobacteria coupled with a non-significant reduction in Clostridia and Bacteroidia in people with PD. Clostridia and Bacteroidia are typically abundant throughout the
FIGURE 4 | Gammaproteobacteria-produced LPS treatment increases intestinal permeability in vitro. IEC-6 cells express TLR4, a known LPS receptor (A). Acute LPS treatment (10 µg/ml for 4 h) resulted in a noticeable reduction of and alteration in the distribution of ZO-1 (B) and e-Cadherin (C).
healthy gut lumen (Lloyd-Price et al., 2016), and in this study were non-significantly reduced in mild and severe PD groups compared to healthy controls. Clostridia mostly consist of commensal bacteria located in the gastrointestinal mucosa, and genera including Blautia, Faecalibacterium and Ruminococcus are widely considered the principal producers of the anti-inflammatory metabolite butyrate (Sokol et al., 2008). Clostridium tyrobutyricum and various Bifidobacteria strains protect against LPS-induced inflammation and alterations to tight junction proteins in vitro (Riedel et al., 2006; Xiao et al., 2018). Interestingly, it has recently been reported that bacteria within Bacteroidia secrete an immunoinhibitory form of LPS which silences proinflammatory TLR4 signaling (d’Hennezel et al., 2017). Conversely, Gammaproteobacteria and Verrucomicrobiae, which normally represent only a small proportion of the healthy adult gut microbiome, are considered to be important for immune patterning and maintenance of mucin integrity (Eckburg et al., 2005). However, the abundance of Gammaproteobacteria is positively associated with metabolic disorders, inflammation and cancer, where increased Proteobacteria abundance is a proposed marker for dysbiosis (Shin et al., 2015). As a major contributor to LPS production, the finding of markedly elevated Gammaproteobacteria coupled with reduced Clostridia and Bacteroidia in both the mild and severe PD groups provides a basis for increased luminal LPS levels and reduced commensal, anti-inflammatory action in PD, which may impair intestinal integrity and cause chronic intestinal inflammation (Finnie et al., 1995; Lührs et al., 2002; Guo et al., 2015; Nighot et al., 2017). In low levels, Akkermansia, the only genus within Verrucomicrobiae, typically represent 1–4% of the gut microbiome and are beneficial mucin degraders that promote intestinal barrier turnover (Collado et al., 2007; Derrien et al., 2008). However, Akkermansia muciniphila exacerbates Salmonella-induced inflammation in gnotobiotic mice due to disruption of the protective mucus layer (Ganesh et al., 2013). Consequently, although both PD groups exhibited reduced commensal bacterial action, when coupled with high levels of Verrucomicrobiae in the severe PD group this may increase intestinal leakiness, facilitating translocation of luminal LPS to the enteric nervous system or systemic circulation. Systemic LPS has been linked to intestinal inflammation, which in turn is associated with enteric αSyn aggregation (Forsyth et al., 2011; Devos et al., 2013; Kelly et al., 2014). Alternatively, the elevated levels in severe patients may be a product of longer disease duration as Verrucomicrobiae thrive in low nutrient environments (Sonoyama et al., 2009). More thorough characterization of the gut microbiome, metabolomic profiling and intestinal protein expression is required in a larger sample size to clarify the influence of the gut microbiome on intestinal dysfunction in PD.

We subsequently examined if elevated CNS αSyn levels are associated with alterations in the gut microbiome prior to the

![FIGURE 5](image-url)
onset of motor symptoms in Thy1-αSyn mice. Thy-1 promoter activity does not begin until postnatal day 10 (Chesselet et al., 2012; Hallett et al., 2012), which may underlie the progressive accumulation of human and total αSyn between 4 and 12 weeks of age, however, further studies are required to characterize αSyn levels throughout the brain and peripheral nervous system of Thy1-αSyn mice at different time points. Bacteroidia, Clostridia and Bacilli dominated the microbiome in both WT and Thy1-αSyn mice while Gammaproteobacteria abundance was very low, reflecting previous microbial profiling in healthy lab mice (Hildebrandt et al., 2013). Antibiotic use, Clostridium difficile-associated colitis and high fat diets are associated with increased Proteobacteria and Gammaproteobacteria abundance in mice (Cani et al., 2008; Hildebrandt et al., 2009; Reeves et al., 2011). However, despite progressively increasing αSyn levels in the brain, there was no evidence of a pro-inflammatory microbial signature in Thy1-αSyn mice. As other models induce PD symptoms and deficits through environmental triggers (e.g., Rotenone or MPTP treatment) (Johnson et al., 2018; Sun et al., 2018; Yang et al., 2018), or exacerbate PD pathology by oral bacterial administration (Choi et al., 2018) or altering the gut microbiome (Sampson et al., 2016), this suggests that elevated central αSyn levels alone may not drive early intestinal changes in PD. As such, our findings from clinical studies and Thy1-αSyn mice further strengthen evidence for a causative link between microbial dysbiosis and PD progression, supporting a previously reported pathological spread of αSyn from the gut to the CNS in PD pathogenesis (Braak et al., 2006; Hawkes et al., 2007; Tomé et al., 2013; Holmqvist et al., 2014; Stokholm et al., 2016).

As various studies have implicated microbially-derived LPS in PD pathogenesis (Forsyth et al., 2011; He et al., 2013; Kelly et al., 2014; Sharma and Nehru, 2015; Choi et al., 2018), this study was the first to investigate the role of LPS as a catalyst for intestinal permeability and phenotypic change in Thy1-αSyn mice. In vitro, a 4-hour LPS treatment noticeably reduced tight junction protein levels (ZO-1 and e-Cadherin) around the cell membrane. Following a 12-day oral LPS treatment, we observed a significant increase in hind-limb clasp score with the tail suspension test in the Thy1-αSyn, but did not observe more severe motor impairments in treated Thy1-αSyn or WT mice, contrary to prior studies utilizing LPS or Thy1-αSyn mice in the context of PD. Previously, an intraperitoneal injection of LPS into healthy C57/BL6 mice resulted in elevations in both normal and aggregated αSyn throughout the large intestine, with a concomitant increase in intestinal permeability, between 3 and 5 months post-LPS treatment (Kelly et al., 2014). Similarly, intranoral administration of LPS to healthy mice every second day for 5 months caused progressive hypokinesia, nigrostriatal αSyn aggregation, selective dopaminergic neuronal loss and accompanying reduction in striatal dopamine, with no evidence of systemic inflammation or immune activation (He et al., 2013). Although these studies demonstrated the marked influence of systemic LPS-induced inflammation on PD pathogenesis in mice, the current study sought to investigate the interaction between a genetic predisposition for PD and intestinal LPS. The failure of Thy1-αSyn mice to develop more severe motor impairments after 12 days of oral LPS treatment may be due to the low dose and less invasive route of administration, which was chosen to mimic more clinically relevant chronic intestinal LPS exposure. As such, future studies in this model should investigate the effects of administering chronic and higher doses of oral LPS, as well as to older mice. Recently, chronic stress exacerbated rotenone-induced PD pathology in mice, increasing intestinal hyper-permeability, markers of oxidative stress, neuroinflammation and fecal Akkermansia levels while altering tight junction proteins (Dodiya et al., 2018). Similarly, future studies should characterize the combined influence of different PD risk factors in rodent models, such as environmental toxins and diet.

Microbial dysbiosis may underlie the associations between environmental toxins, pathogens and dietary factors with PD. Rotenone exposure, a Western diet (low fiber/high processed carbohydrate) or high fat diets are linked with dysbiosis, inflammation and PD-like symptoms in rodents (Cani et al., 2008; Hildebrandt et al., 2009; Martinez-Medina et al., 2014; Johnson et al., 2018; Yang et al., 2018), while pesticide and manganese exposure are associated with PD risk (Smyth et al., 1973; Van Der Mark et al., 2011; Kamel et al., 2014). Conversely, exercise, plant-based and Mediterranean diets are associated with a healthy gut microbiome (Tomasel et al., 2016) as well as reduced PD risk and later age of onset (Alcalay et al., 2012), strengthening evidence for environmental modulation of the gut microbiome in PD.

Overall, this study strengthens increasing evidence for a complex interaction between environmental and genetic determinants of PD, where dysbiosis and gastrointestinal dysfunction may act as a catalyst for αSyn pathophysiology and eventual neurodegeneration. Future studies should explore the cumulative risk of various genetic variants involved in immune regulation and intestinal integrity coupled with environmental factors such as nutrition, drug and toxin exposure, and microbial composition. Although a crucial regulator of the gastrointestinal environment, the gut microbiome is easily manipulated, and thus provides an exciting avenue for future clinical interventions to modify the natural course and severity of symptoms in PD.

DATA AVAILABILITY

There is no dataset.

AUTHOR CONTRIBUTIONS

SD, FM, and RA contributed to design of the study. AG, LP, and FK completed in vivo characterization. AG, CG, GM, and RA conducted in vitro experiments. MB and JK collected and analyzed the clinical patient data. AG and LP performed the statistical analysis. FM, AA, and RA aided with analysis and interpretation. AG and RA wrote the first draft of the manuscript. LP, SD, FM, AA, FK, and RA contributed to critical revision and editing of the manuscript.
FUNDING
This work was supported by funding from the Parkinson’s WA Zrinski Research Grant, and the Pierce-Armstrong Foundation.

ACKNOWLEDGMENTS
The authors would like to acknowledge Parkinson’s WA and the Pierce-Armstrong Foundation for funding support, and Alexa Jefferson, Sue Walters and the Movement Disorders Clinic neurologists for clinical support. The authors would also like to acknowledge the staff at Ozgene for support with animal husbandry and treatments.

REFERENCES
Adams-Carr, K. L., Bestwick, J. P., Shribman, S., Lees, A., Schrag, A., and Noyce, A. J. (2016). Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 87, 719–716. doi: 10.1136/jnnp-2015-311680
Alcalay, R. N., Gu, Y., Mejia-Santana, H., Cote, L., Marder, K. S., and Scarmeas, N. (2012). The association between Mediterranean diet adherence and Parkinson’s disease. Mov. Disord. 27, 771–774. doi: 10.1002/mds.24918
Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lee, L., White, C. L., et al. (2010). Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689–702. doi: 10.1007/s00401-010-0664-3
Braak, H., de Vos, R. A., Bohl, J., and Del Tredici, K. (2006). Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. Lett. 396, 67–72. doi: 10.1016/j.neulet.2005.11.012
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481. doi: 10.2373/dbi.07-0413
Carroll, I. M., Ringel-Kulka, T., Keku, T. O., Chang, Y.-H., Packey, C. D., Sartor, R. B., et al. (2011). Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G799–G807. doi: 10.1152/ajpgi.00154.2011
Chaudhuri, K. R., Healy, D. G., and Schapira, A. H. (2006). Non-motor symptoms of Parkinson’s disease. Lancet Neurol. 5, 235–245.
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M., and Subramaniam, S. (2017). Extended “Timed Up and Go” assessment as a clinical indicator of cognitive state in Parkinson’s disease. J. Neurol. Sci. 375, 86–91. doi: 10.1016/j.jns.2017.01.050
Finnie, I., Dwarkanath, A., Taylor, B., and Rhodes, J. (1995). Colonic mucin synthesis is increased by sodium butyrate. Gut 36, 93–99. doi: 10.1136/gut.36.1.93
Goedert, M., Spillantini, M. G., Del Tredici, K., and Braak, H. (2013). 100 years of Parkinson disease. Acta Neuropathol. 125, 67–72. doi: 10.1007/s00401-012-0999-3
Gorecki et al. 2019 | Volume 13 | Article 839

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2019.00839/full#supplementary-material
Heintz-Buschart, A., Pandey, U., Wicke, T., Sixel-Döring, F., Janzen, A., Sittig-Wiegand, E., et al. (2018). The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 33, 88–98. doi: 10.1002/mds.27105

Hildebrand, F., Nguyen, T. L. A., Brinkman, B., Yunta, R. G., Cauwe, B., Vandenameule, P., et al. (2013). Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol. 14:R4. doi: 10.1186/gb-2013-14-1-r4

Hildebrandt, M. A., Hoffmann, C., Sherrill–Mix, S. A., Keilbaugh, S. A., Hamady, M., Chen, Y. Y., et al. (2009). High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1716.e2–1716.e2. doi: 10.1053/j.gastro.2009.08.042

Hill-Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., et al. (2017). Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739–749. doi: 10.1002/mds.26942

Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., et al. (2016). Pathological ferromanganese alloy. Acta Neuropathol. 131, 559–575. doi: 10.1007/s00401-016-1735-0

Hillebrandt, S., Mendiz, M., Denizot, J., Dreux, N., Robin, F., Billard, E., Bonnet, R., et al. (2014). Western diet induces dysbiosis with increased E coli in CEACAM10 mice, alters host barrier function favouring AIEC colonisation. Gut 63, 116–124. doi: 10.1136/gutjnl-2012-304119

Martínez-Martin, P., Rodríguez-Blaquez, C., Kurtis, M. M., Chaudhuri, K. R., and Group, N. V. (2011). The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov. Disord. 26, 399–406. doi: 10.1002/mds.23462

Nighot, M., Al-Sadi, R., Guo, S., Rawat, M., Nighot, P., Watterson, M. D., et al. (2017). Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4/Myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression. Am. J. Physiol. Gastrointest. Liver Physiol. 31, 2698–2710. doi: 10.1152/ajpgi.00004.2017

Otto, S., Musfeldt, D., Wenderoth, D., Happe, J., Brant, O., Fülsch, U., et al. (2004). Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53, 685–693. doi: 10.1136/gut.2003.025403

Ouyang, Y. (2012). Direct Data Submission 2012/03/09. MGI Dir. Data Submission. Available at: http://www.informatics.jax.org/reference/j181092

Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., et al. (2018). Anti–tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 75, 939–946. doi: 10.1001/jamaneurol.2017.7581

Reeves, A. E., Theriot, C. M., Bergin, I. L., Huffnagle, G. B., Schloss, P. D., and Young, V. B. (2011). The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2, 145–158. doi: 10.4161/gmic.2.3.16333

Reyes, A., Haynes, M., Hanson, N., Angly, F. E., Heath, A. C., Rohwer, F., et al. (2010). Viruses in the faecal microbiota of monzygotic twins and their mothers. Nature 466, 334–338. doi: 10.1038/nature09199

Riedel, C. U., Foata, F., Philippe, D., Adolfsen, O., Eikmanns, B. J., and Blüm, S. (2006). Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation. World J. Gastroenterol. 12:3729. doi: 10.3748/wjg.v12.i23.3729

Sampson, T. R., Debelius, J. W., Thron, T., Jansen, S., Shastri, G. G., Ilhan, Z. E., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167, 1469.e12–1480.e12. doi: 10.1016/j.cell.2016.11.018

Scheperjans, F., Al, V., Pereira, P. A., Koskinen, K., Paulin, L., Pekkonen, E., et al. (2015). Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov. Disord. 30, 350–358. doi: 10.1002/mds.26069

Sharma, N., and Nehru, B. (2015). Characterization of the lipopolysaccharide induced model of Parkinson's disease: role of oxidative stress and neuroinflammation. Neurochem. Int. 87, 92–105. doi: 10.1016/j.neuci.2015.06.004

Shin, N.-R., Whon, T. W., and Bae, J.-W. (2015). Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 33, 496–503. doi: 10.1016/j.tibtech.2015.06.011

Smyth, L. T., Ruhl, R., Whitman, N., and Dugan, T. (1973). Clinical manganism and exposure to manganese in the production and processing of ferromanganese alloy. J. Occup. Environ. Med. 15, 101–109.

Sokol, H., Pigneur, B., Watterlot, L., Labadie, O., Bermejó-Humárán, L. G., Grataudoux, J.-L., et al. (2008). Facelabacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731–16736. doi: 10.1073/pnas.0804812105

Sonoyama, K., Fujiwara, R., Takemura, N., Ogasawara, T., Watanabe, J., Ito, H., et al. (2009). Response of gut microbiota to fasting and hibernation in Syrian hamsters. Appl. Environ. Microbiol. 75, 6451–6456. doi: 10.1128/AEM.00692-09

Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J., and Borghammer, P. (2016). Pathological α-synuclein gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940–949. doi: 10.1002/ana.24648

Suffredini, A. F., Hochstein, H. D., and McMahon, F. G. (1999). Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new
clinical lot of *Escherichia coli* O:113 endotoxin. *J. Infect. Dis.* 179, 1278–1282. doi: 10.1086/314717

Sun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., et al. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. *Brain Behav. Immun.* 70, 48–60. doi: 10.1016/j.bbi.2018.02.005

Tomasello, G., Mazzola, M., Leone, A., Sinagra, E., Zummo, G., Farina, F., et al. (2016). Nutrition, oxidative stress and intestinal dysbiosis: influence of diet on gut microbiota in inflammatory bowel diseases. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.* 160, 461–466. doi: 10.5507/bp.2016.052

Tomé, C. M. L., Tyson, T., Rey, N. L., Grathwohl, S., Britschgi, M., and Brundin, P. (2013). Inflammation and α-Synuclein’s prion-like behavior in Parkinson’s disease—is there a link? *Mol. Neurobiol.* 47, 561–574.

Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippet, H., Bürmann, J., et al. (2016). Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. *Parkinsonism Relat. Disord.* 32, 66–72. doi: 10.1016/j.parkreldis.2016.08.019

Van Der Mark, M., Brouwer, M., Kromhout, H., Nijssen, P., Huss, A., and Vermeulen, R. (2011). Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. *Environ. Health Perspect.* 120, 340–347. doi: 10.1289/ehp.1103881

Weimers, P., Halfvarson, J., Sachs, M. C., Saunders-Pullman, R., Ludvigsson, J. F., Peter, L., et al. (2018). Inflammatory bowel disease and Parkinson’s disease: a nationwide swedish cohort study. *Inflamm. Bowel Dis.* 25, 111–123. doi: 10.1093/ibd/izy190

Xiao, Z., Liu, L., Tao, W., Pei, X., Wang, G., and Wang, M. (2018). *Clostridium tyrobutyricum* protect intestinal barrier function from LPS-induced apoptosis via P38/JNK signaling pathway in IPEC-J2 cells. *Cell. Physiol. Biochem.* 46, 1779–1792. doi: 10.1159/000489364

Yang, X., Qian, Y., Xu, S., Song, Y., and Xiao, Q. (2018). Longitudinal analysis of fecal microbiome and pathologic processes in a rotenone induced mice model of Parkinson’s disease. *Front. Aging Neurosci.* 9:441. doi: 10.3389/fnagi.2017.00441

Zhang, J., Saur, T., Duke, A. N., Grant, S. G., Platt, D. M., Rowlett, J. K., et al. (2014). Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. *J. Neurogenet.* 28, 98–111. doi: 10.3109/01677063.2014.892486

Conflict of Interest Statement: LP and FK are employed by Ozgene Pty Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Gorecki, Preskey, Bakeberg, Kenna, Gildenhuys, MacDougall, Dunlop, Mastaglia, Akkari, Koengten and Anderton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.